Abstract
Non alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and considered to be the commonest liver disorder in Western countries. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through non-alcoholic steatohepatitis (NASH) to fat with fibrosis and ultimately cirrhosis. Simple steatosis is largely benign and non-progressive, whereas NASH, characterized by hepatocyte injury, inflammation and fibrosis can lead to cirrhosis, liver failure and hepatocellular carcinoma (HCC). NAFLD is strongly associated with obesity, insulin resistance, hypertension and dyslipidaemia and is now regarded as the liver manifestation of the metabolic syndrome. Rapid spread of the obesity ‘pandemic’ in adults and children, coupled with the realisation that the outcomes of obesity-related liver disease are not entirely benign, has led to rapid growth in clinical and basic studies in NAFLD over the past decade. These studies are now beginning to inform management strategies for patients with NAFLD.
Keywords: Fatty liver, Non-alcoholic steatohepatitis, metabolic syndrome, obesity, insulin resistance
Current Pharmaceutical Design
Title: Current and Future Therapeutic Strategies in NAFLD
Volume: 16 Issue: 17
Author(s): Nimantha Mark Wilfred de Alwis and Christopher Paul Day
Affiliation:
Keywords: Fatty liver, Non-alcoholic steatohepatitis, metabolic syndrome, obesity, insulin resistance
Abstract: Non alcoholic fatty liver disease (NAFLD) is increasingly diagnosed worldwide and considered to be the commonest liver disorder in Western countries. It comprises a disease spectrum ranging from simple steatosis (fatty liver), through non-alcoholic steatohepatitis (NASH) to fat with fibrosis and ultimately cirrhosis. Simple steatosis is largely benign and non-progressive, whereas NASH, characterized by hepatocyte injury, inflammation and fibrosis can lead to cirrhosis, liver failure and hepatocellular carcinoma (HCC). NAFLD is strongly associated with obesity, insulin resistance, hypertension and dyslipidaemia and is now regarded as the liver manifestation of the metabolic syndrome. Rapid spread of the obesity ‘pandemic’ in adults and children, coupled with the realisation that the outcomes of obesity-related liver disease are not entirely benign, has led to rapid growth in clinical and basic studies in NAFLD over the past decade. These studies are now beginning to inform management strategies for patients with NAFLD.
Export Options
About this article
Cite this article as:
Mark Wilfred de Alwis Nimantha and Paul Day Christopher, Current and Future Therapeutic Strategies in NAFLD, Current Pharmaceutical Design 2010; 16 (17) . https://dx.doi.org/10.2174/138161210791208901
DOI https://dx.doi.org/10.2174/138161210791208901 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Insulin Resistance in the HIV-Infected Population: The Potential Role of Mitochondrial Dysfunction
Current Drug Targets - Infectious Disorders Hypertension in Egypt: A Systematic Review
Current Hypertension Reviews VIP as a Potential Therapeutic Agent in Gram Negative Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell-Penetrating Peptides as a Potential Drug Delivery System for Effective Treatment of Diabetes
Current Pharmaceutical Design Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews A Systematic Review of Randomized Controlled Trials Examining the Nephroprotective Properties of Antihypertensive Medications
Current Hypertension Reviews Molecular Cloning of a Novel PPEF-1 Gene Variant from a T-Cell Lymphoblastic Lymphoma Cell Line
Recent Patents on DNA & Gene Sequences Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Investigation on the Development of Losartan Potassium Sustained Release Microspheres by Solvent Evaporation Methods
Micro and Nanosystems Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?
Current Vascular Pharmacology ACE Inhibitors and ARBs for Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Changes in Menopause
Current Cardiology Reviews The Cannabinoids Switch of Oxidative Stress: A Double-Edged Sword
Mini-Reviews in Organic Chemistry Evaluation of the Pulmonary Veins and Left Atrial Volume using Multidetector Computed Tomography in Patients Undergoing Catheter Ablation for Atrial Fibrillation
Current Cardiology Reviews Role of Ox-LDL and LOX-1 in Atherogenesis
Current Medicinal Chemistry Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Perspectives of Choroidal Neovascularization Therapy
Current Drug Targets